Back to today’s briefing

Story perspectives

Eli Lilly's Revenue Soars, Shares Plunge Amid Competition

5/2/2025

23 3

Summary

Lilly's Revenue Surge

Eli Lilly's Q1 revenue skyrocketed by 45% to $12.73 billion, fueled by booming sales of its weight loss drug. Yet, shares plummeted 10% as earnings fell short of expectations, facing stiff competition from Novo Nordisk's Wegovy. CEO Dave Ricks voiced worries about looming pharmaceutical tariffs while highlighting a bold $27 billion investment plan to enhance U.S. production.

Summary

Ricks Advocates Domestic Production

Eli Lilly's CEO, Dave Ricks, raised alarms over national security as potential pharmaceutical tariffs loom. He urged for a shift towards domestic production of vital generic drugs, predominantly manufactured abroad. Ricks challenged the efficacy of tariffs, arguing that existing industry investments could effectively revitalize supply chains and ensure access to essential medicines.

1 of 2

Lilly's Revenue Surge

Eli Lilly's Q1 revenue skyrocketed by 45% to $12.73 billion, fueled by booming sales of its weight loss drug. Yet, shares plummeted 10% as earnings fell short of expectations, facing stiff competition from Novo Nordisk's Wegovy. CEO Dave Ricks voiced worries about looming pharmaceutical tariffs while highlighting a bold $27 billion investment plan to enhance U.S. production.

1 / 2